Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 778

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 778
---
 ​ |
| Diluted:                                           |    ​ | ​ | ​                               | ​ |         ​ | ​ |    ​ | ​ | ​ | ​ |         ​ | ​ |    ​ | ​ | ​                              | ​ |         ​ | ​ |    ​ | ​ | ​ | ​ |         ​ | ​ | ​ |
| Weighted average common shares outstanding – Basic |    ​ | ​ | ​                               | ​ | 4,570,320 | ​ |    ​ | ​ | ​ | ​ | 4,519,641 | ​ |    ​ | ​ | ​                              | ​ | 4,559,944 | ​ |    ​ | ​ | ​ | ​ | 4,503,187 | ​ | ​ |
| Common stock equivalents*                          |    ​ | ​ | ​                               | ​ |         — | ​ |    ​ | ​ | ​ | ​ |         — | ​ |    ​ | ​ | ​                              | ​ |         — | ​ |    ​ | ​ | ​ | ​ |         — | ​ | ​ |
| Denominator for diluted net loss per share         |    ​ | ​ | ​                               | ​ | 4,570,320 | ​ |    ​ | ​ | ​ | ​ | 4,519,641 | ​ |    ​ | ​ | ​                              | ​ | 4,559,944 | ​ |    ​ | ​ | ​ | ​ | 4,503,187 | ​ | ​ |

* No amounts were considered as their effects would be anti-dilutive. Basic and diluted net loss per share are computed as follows:

| ​                                           
 ​                                           | ​    
 2024 | ​ | Three Months EndedSeptember 30, |   |         ​ | ​ | 2023 |   |   |   |         ​ | ​ | ​    
 2024 | ​ | Nine Months EndedSeptember 30, |   |         ​ | ​ | 2023 |   |   |   |         ​ |   | ​ |
|:--------------------------------------------|:-----|:--|:--------------------------------|:--|----------:|:--|:-----|:--|:--|:--|----------:|:--|:-----|:--|:-------------------------------|:--|----------:|:--|:-----|:--|:--|:--|----------:|:--|:--|
| Net loss –�